Source:http://linkedlifedata.com/resource/pubmed/id/21117025
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2010-11-30
|
pubmed:abstractText |
Gallbladder cancer (GBC) is the main cause of death by malignant tumour in women in Chile. There is no information regarding the role of excision repair cross-complementing group 1 (ERCC1) in GBC. Our aim is to determine the expression and significance of ERCC1 as a prognostic factor in GBC. Tissue microarrays were prepared using 200 surgically resected GBCs and 50 non-malignant gallbladders as controls. In 190 cases, ERCC1 was determined by immunohistochemistry. The correlation between ERCC1 expression and GBC pathological characteristics and patient survival were analysed. Ninety-five percent of the non-malignant gallbladder epithelia showed intense and diffuse ERCC1 expression. GBC cases showed ERCC1 expression in the tumour cells in 100/190 (53%) cases. The best differentiated tumours showed significantly greater expression than the less differentiated (p<0.05). Patients with ERCC1-positive status with subserosal carcinomas (pT2) had significantly better survival than ERCC1-negative patients at 20 and 60 months of follow-up (p=0.005), and the probability of dying was 6 times lower for ERCC1-positive than for ERCC1-negative patients. Our preliminary results show that chole-cystectomised patients with GBC in stage pT2 and with ERCC1 expression have significantly better survival than patients at the same stage that did not present ERCC1 expression.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1699-5848
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
37-43
|
pubmed:meshHeading |
pubmed-meshheading:21117025-Aged,
pubmed-meshheading:21117025-Aged, 80 and over,
pubmed-meshheading:21117025-Case-Control Studies,
pubmed-meshheading:21117025-Chile,
pubmed-meshheading:21117025-DNA-Binding Proteins,
pubmed-meshheading:21117025-Endonucleases,
pubmed-meshheading:21117025-Female,
pubmed-meshheading:21117025-Gallbladder Neoplasms,
pubmed-meshheading:21117025-Humans,
pubmed-meshheading:21117025-Immunohistochemistry,
pubmed-meshheading:21117025-Kaplan-Meier Estimate,
pubmed-meshheading:21117025-Male,
pubmed-meshheading:21117025-Middle Aged,
pubmed-meshheading:21117025-Neoplasm Staging,
pubmed-meshheading:21117025-Prognosis,
pubmed-meshheading:21117025-Protein Array Analysis
|
pubmed:year |
2011
|
pubmed:articleTitle |
ERCC1 (excision repair cross-complementing 1) expression in pT2 gallbladder cancer is a prognostic factor.
|
pubmed:affiliation |
Pathology Service, Clinica Alemana de Santiago, Faculty of Medicine, Universidad del Desarrollo, Santiago, Chile. iroa@alemana.cl
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|